De novo lipogenesis and hypercaloric diets are thought to contribute to increased fat mass, particularly in abdominal fat depots. CB1 is highly expressed in adipose tissue, and CB1-mediated signalling is associated with stimulation of lipogenesis and diet-induced obesity, though its contribution to increasing fat deposition in adipose tissue is controversial. Lipogenesis is regulated by transcription factors such as liver X receptor (LXR), sterol-response element binding protein (SREBP) and carbohydrate-responsive-element-binding protein (ChREBP). We evaluated the role of CB1 in the gene expression of these factors and their target genes in relation to lipogenesis in the perirenal adipose tissue (PrAT) of rats fed a high-carbohydrate diet (HCHD) or a high-fat diet (HFD). Both obesity models showed an up-regulated gene expression of CB1 and Lxrα in this adipose pad. The Srebf-1 and ChREBP gene expressions were down-regulated in HFD but not in HCHD. The expression of their target genes encoding for lipogenic enzymes showed a decrease in diet-induced obesity and was particularly dramatic in HFD. In HCHD, CB1 blockade by AM251 reduced the Srebf-1 and ChREBP expression and totally abrogated the remnant gene expression of their target lipogenic enzymes. The phosphorylated form of the extracellular signal-regulated kinase (ERK-p), which participates in the CB1-mediated signalling pathway, was markedly present in the PrAT of obese rats. ERK-p was drastically repressed by AM251 indicating that CB1 is actually functional in PrAT of obese animals, though its activation loses the ability to stimulate lipogenesis in PrAT of obese rats. Even so, the remnant expression levels of lipogenic transcription factors found in HCHD-fed rats are still dependent on CB1 activity. Hence, in HCHD-induced obesity, CB1 blockade may help to further potentiate the reduction of lipogenesis in PrAT by means of inducing down-regulation of the ChREBP and Srebf-1 gene expression, and consequently in the expression of lipogenic enzymes.
References
[1]
Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54; 254–260.
[2]
Cinti S (1999) The Adipose Organ. Milan, Italy: Kurtiss.
[3]
Miyashita Y, Koide N, Ohtsuka M, Ozaki H, Itoh Y, et al. (2004) Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity. Diabetes Res Clin Pract 65: 235–241. doi: 10.1016/j.diabres.2004.01.008
[4]
Sasakabe T, Haimoto H, Umegaki H, Wakai K (2011) Effects of a moderate low-carbohydrate diet on preferential abdominal fat loss and cardiovascular risk factors in patients with type 2 diabetes. Diabetes Metab Syndr Obes 4: 167–174. doi: 10.2147/dmso.s19635
[5]
Strable M S, Ntambi JM (2010) Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol 45: 199–214. doi: 10.3109/10409231003667500
[6]
Cha JY, Repa JJ (2007) The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 282: 743–751. doi: 10.1074/jbc.m605023200
[7]
Morgan K, Uyuni A, Nandgiri G, Mao L, Castaneda L, et al. (2008) Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 20: 843–854. doi: 10.1097/meg.0b013e3282f9b203
[8]
Minehira K, Vega N, Vidal H, Acheson K, Tappy L (2004) Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. Int J Obes Relat Metab Disord 28: 1291–1298. doi: 10.1038/sj.ijo.0802760
[9]
Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M (2002) Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab 282: E46–51.
[10]
Ortega FJ, Mayas D, Moreno-Navarrete JM, Catalan V, Gomez-Ambrosi J, et al. (2009) The gene expression of the main lipogenic enzymes is downregulated in visceral adipose tissue of obese subjects. Obesity (Silver Spring) 18: 13–20. doi: 10.1038/oby.2009.202
[11]
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548–2556. doi: 10.1210/jc.2004-0395
[12]
Pagano C, Rossato M, Vettor R (2008) Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol 20 Suppl 1, 124–129.
[13]
Nicklas BJ, Penninx BW, Cesari M, Kritchevsky SB, Newman AB, et al. (2004) Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging and Body Composition Study. Am J Epidemiol 160: 741–749. doi: 10.1093/aje/kwh281
[14]
Carr MC, Brunzell JD (2004) Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89: 2601–2607. doi: 10.1210/jc.2004-0432
[15]
Piche ME, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J, Lemieux S (2005) Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. Diabetes 54: 770–777. doi: 10.2337/diabetes.54.3.770
[16]
Britton KA, Fox CS (2011) Perivascular adipose tissue and vascular disease. Clin Lipidol 6: 79–91. doi: 10.2217/clp.10.89
[17]
Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423–431. doi: 10.1172/jci17725
[18]
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73–100. doi: 10.1210/er.2005-0009
[19]
Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053–3060. doi: 10.2337/db06-0812
[20]
Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143: 315–317. doi: 10.1007/s002130050953
[21]
Kirkham TC (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16: 297–313. doi: 10.1097/00008877-200509000-00004
[22]
Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40: 2–14.
[23]
Crespillo A, Suárez J, Bermudez-Silva FJ, Rivera P, Vida M, et al. (2010) Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J 433: 175–185. doi: 10.1042/bj20100751
[24]
Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298–1305. doi: 10.1172/jci200523057
[25]
Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, et al. (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118: 3160–3169. doi: 10.1172/jci34827
[26]
Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G (2006) The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (Lond) 30 Suppl 1, S33–38.
[27]
Wu HM, Yang YM, Kim SG (2011) Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Galpha i/o inhibition. Mol Pharmacol 80: 859–869. doi: 10.1124/mol.111.072769
[28]
Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, et al. (2013) Metabolic effects of chronic cannabis smoking. Diabetes Care 36: 2415–2422. doi: 10.2337/dc12-2303
Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174. doi: 10.1172/jci200113505
[31]
Yap F, Craddock L, Yang J (2011) Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci 7: 645–650. doi: 10.7150/ijbs.7.645
[32]
Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG (2009) Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49: 1913–1925. doi: 10.1002/hep.22887
[33]
Uyeda K, Yamashita H, Kawaguchi T (2002) Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage. Biochem Pharmacol 63: 2075–2080. doi: 10.1016/s0006-2952(02)01012-2
[34]
Kawaguchi T, Takenoshita M, Kabashima T, Uyeda K (2001) Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc Natl Acad Sci U S A 98: 13710–13715. doi: 10.1073/pnas.231370798
[35]
Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B et al. (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: (Pt 2) 637–641.
[36]
Bost F, Aouadi M, Caron L, Binetruy B (2005) The role of MAPKs in adipocyte differentiation and obesity. Biochimie 87: 51–56. doi: 10.1016/j.biochi.2004.10.018
[37]
Kotzka J, Knebel B, Haas J, Kremer L, Jacob S, et al. (2012) Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity. PLoS One 7, e32609.
[38]
Lan R, Liu Q, Fan P, Lin S, Fernando SR, et al. (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 42: 769–776. doi: 10.1021/jm980363y
Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19. doi: 10.1186/gb-2007-8-2-r19
[41]
Chambers AP, Sharkey KA, Koopmans HS (2004) Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat. Physiol Behav 82: 863–869. doi: 10.1016/j.physbeh.2004.07.004
[42]
Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, et al. (2007) Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 282: 11687–11695. doi: 10.1074/jbc.m611911200
[43]
Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, et al. (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 5, e8792.
[44]
Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, et al. (2008) Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol 286: S66–78. doi: 10.1016/j.mce.2008.01.026
[45]
Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, et al. (2008) Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16: 553–565. doi: 10.1038/oby.2007.106
[46]
Engeli S (2008) Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade. Obes Facts 1: 8–15. doi: 10.1159/000114255
[47]
Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29: 415–445. doi: 10.1146/annurev-immunol-031210-101322
[48]
Zelcer N, Tontonoz P (2006) Liver X Receptors as integrators of metabolic and inflammatory signaling. The J. Clin Invest 116: 607–614. doi: 10.1172/jci27883
[49]
Yu R, Kim CS, Kwon BS, Kawada T (2006) Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity 14: 1353–1362. doi: 10.1038/oby.2006.153
[50]
Chascione C, Elwyn DH, Davila M, Gil KM, Askanazi J, Kinney JM (1987) Effect of carbohydrate intake on de novo lipogenesis in human adipose tissue. Am J Physiol 253: E664–669.
[51]
Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD (2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97: 11371–11376. doi: 10.1073/pnas.97.21.11371
[52]
Kotzka J, Muller-Wieland D, Roth G, Kremer L, Munck M, et al. (2000) Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade. J Lipid Res 41: 99–108.
[53]
Roth G, Kotzka J, Kremer L, Lehr S, Lohaus C, et al. (2000) MAP kinases Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro. J Biol Chem 275: 33302–33307. doi: 10.1074/jbc.m005425200
[54]
Greenberg AS, Shen WJ, Muliro K, Patel S, Souza SC, et al. (2001) Stimulation of lipolysis and hormone-sensitive lipase via the extracellular signal-regulated kinase pathway. J Biol Chem 276: 45456–45461. doi: 10.1074/jbc.m104436200
